Thomas K Equels insider trades

Open-market stock purchases and sales by Thomas K Equels, CEO & President at AIM ImmunoTech Inc, from SEC Form 4 filings since Dec 10, 2021.

Track record: 61% of 18 scored buys are up 5% or more since purchase, averaging +47%.

Recent trades

DateStockTradeValue
Mar 12, 2026AIM AIM ImmunoTech IncBought (not open market)—
Mar 12, 2026AIM AIM ImmunoTech IncBought (not open market)—
Mar 6, 2026AIM AIM ImmunoTech IncBought (not open market)—
Mar 6, 2026AIM AIM ImmunoTech IncBought (not open market)$625K

Companies traded

  • AIM AIM ImmunoTech Inc: 21 buys, last Mar 12, 2026

Get free alerts when Thomas K Equels files a new trade →